Benzinga | May 20, 2021 07:07AM EDT

Forma Therapeutics to Present Data from Pivotal Phase 2 Trial of Olutasidenib at ASCO 2021

Olutasidenib demonstrated a 33.3% composite complete remission rate (CR/CRh) in people living with R/R AML with the IDH1 mutation

Among those with CR/CRh, estimated 18-month survival is 87%; median overall survival has not yet been reached

Duration of response of 13.8 months is longest reported in this treatment setting to date

Favorable tolerability profile following continuous oral treatment with olutasidenib 150mg BID